2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo(b)furan carboxylic acid | 104224-14-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo(b)furan carboxylic acid
• 英文别名: 2-(5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-yl)-1-benzofuran-6-carboxylic acid
• CAS: 104224-14-8
• 化学式: C₂₃H₂₄O₃
• 分子量: 348.442
• InChiKey: PKGKOTXWXABJFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo(b)furan carboxylate 生成 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo(b)furan carboxylic acid
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Use of retinoids for preventing and reducing the size of striae distensae lesions
  申请人：Kligman, Albert M.

  公开号：EP0415458A2

  公开（公告）日：1991-03-06

  Striae distensae lesions may be prevented and/or reduced in size by topically applying to the skin affected with the lesions an effective amount of a retinoid, preferably retinoic acid, preferably by daily application in a dermatologically acceptable vehicle, such as a cream base, at a concentration of about 0.025 to 0.1 weight percent retinoic acid. When applied during the striae rubrae stage, the retinoid may be effective to prevent the formation of striae albae lesions, and when applied in either stage, the retinoid may be effective to reduce the width and depth of the lesions, with improved texture and softness.

  可通过在受皮损影响的皮肤上局部施用有效量的维甲酸（最好是维甲酸）来防止和/或缩小红斑皮损，维甲酸的浓度最好为 0.025 至 0.1 重量百分比。在红斑期施用时，维甲酸可有效防止白斑的形成；在任何一个阶段施用时，维甲酸可有效减少皮损的宽度和深度，并改善质地和柔软度。
• ——
  作者：SHROOT B.、 EUSTACHE J.、 BERNARDON J. -M.

  DOI：——

  日期：——
• Composition pharmaceutique ou cosmétique contenant en association un rétinoîde et un stérol
  申请人：CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA

  公开号：EP0465343B1

  公开（公告）日：1994-06-15
• USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a)
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0808159A1

  公开（公告）日：1997-11-26
• USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
  申请人：Fabius Biotechnology

  公开号：US20210338558A1

  公开（公告）日：2021-11-04

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.